Massive Selection for Vanadium Acetate - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex

Short Description:

Send email to us

Product Detail

Product Tags

Feedback (2)

Our company since its inception, constantly regards product or service high quality as business life, continually improve creation technology, make improvements to product high-quality and consistently strengthen business total high-quality management, in strict accordance together with the national standard ISO 9001:2000 for Neratinib Maleate, 2-(Ethylamino)Ethanol, 10 Mm Ammonium Acetate, Make sure you come to feel absolutely cost-free to speak to us for organization. nd we think we're going to share the ideal trading practical experience with all our retailers.

Massive Selection for Vanadium Acetate - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex Detail:

Product Detail

Name	Eptifibatide
CAS number	188627-80-7
Molecular formula	C35H49N11O9S2
Molecular weight	831.96
EINECS Number	641-366-7
Density	1.60±0.1 g/cm3(Predicted)
Storage conditions	Sealed in dry, store in freezer, under -15°C

Synonyms

Eptifibatideacetatesalt;Eptifibatide,MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2,MPAHARGDWPC-NH2,>99%;MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2;INTEGRELIN;Eptifibatide;N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide;MPA-HAR-GLY-ASP-TRP-PRO-CYS-NH2(DISULFIDEBRIDGE,MPA1-CYS6).

Platelet Glycoprotein Antagonist

Etifibatide (integrilin) is a novel polypeptide platelet glycoprotein IIb/IIIa receptor antagonist, which inhibits platelet aggregation and thrombosis by inhibiting the last common pathway of platelet aggregation. Compared with the monoclonal antibody abciximab, eptifibatide has a stronger, more directional and specific binding to GPIIb/IIIa due to the existence of a single conservative amino acid substitution—lysine to replace arginine. Therefore, it should have a good therapeutic effect in the interventional treatment of acute coronary syndrome. Platelet glycoprotein IIb/IIIa receptor antagonist drugs have been developed a lot, and currently there are 3 kinds of preparations that can be used in clinical internationally, abciximab, eptifibatide and tirofiban. ). There is little experience in the use of platelet glycoprotein GPIIb/IIIa receptor antagonists in China, and the available drugs are also very limited. Only one drug, tirofiban hydrochloride, is on the market. Therefore, a new platelet glycoprotein IIb was developed. /IIIa receptor antagonists are imperative. Domestic eptifibatide is an imitation product produced by Chengdu Sino Biological Products Co., Ltd.

Classification

Classification of Antiplatelet Aggregation Drugs

Antiplatelet aggregation drugs can be roughly divided into three categories: 1. Cyclooxygenase-1 (COX-1) inhibitors, such as aspirin. 2. Inhibit platelet aggregation induced by adenosine diphosphate (ADP), such as clopidogrel, prasugrel, cangrelor, ticagrelor, etc. 3. Platelet glycoprotein Ⅱb/Ⅲa receptor antagonists, such as abciximab, eptifibatide, tirofiban, etc. In addition, there are prostaglandin EP3 receptor inhibitors, newly synthesized chemical components and effective extracts from traditional Chinese medicine.

Product detail pictures:

Related Product Guide:

To regularly increase the management program by virtue from the rule of "sincerely, good religion and high quality are the base of enterprise development", we greatly absorb the essence of linked products internationally, and constantly produce new goods to satisfy the calls for of shoppers for Massive Selection for Vanadium Acetate - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex , The product will supply to all over the world, such as: Portland, Czech, Sierra Leone, we rely on own advantages to build a mutual-benefit commerce mechanism with our cooperative partners. As a result, now we have gained a global sales network reaching the Middle East, Turkey, Malaysia and Vietnamese.

2-Hydroxy-1-Naphthaldehyde